Scottish Enterprise

Lentitek is a cell and gene therapy company focused on developing innovative treatments for cancer patients. The company is dedicated to making advanced therapeutics more accessible by enhancing the production of lentiviral vectors, which are essential for gene therapies. Lentitek employs a proprietary method that utilizes a novel promoter and a triple transfection production process to significantly increase viral yields by tenfold or more. This approach not only improves the efficiency of lentiviral production but also aims to lower production costs for healthcare providers, thereby broadening the availability of its therapies to a larger patient population.

UFraction8 is a developer of innovative bioprocessing technology that specializes in scalable solutions for biomass filtration, separation, and dewatering. The company’s technology is applicable to a diverse range of microorganisms, including microalgae, yeast, and bacteria, allowing for the effective sorting of biomass from culture media without the use of harmful flocculants or traditional methods such as centrifugation and membrane filtration. By utilizing advanced microfluidic devices, uFraction8 enhances throughput for industrial-scale applications, including liquid particle processing and selective concentration of pathogens. This technology offers a cost-effective alternative to conventional liquid processing methods, enabling industries to improve efficiency and reduce expenses in their operations.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Cytomos Limited, established in 2011 and based in Edinburgh, United Kingdom, specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. The company is known for its patented Dielectric Spectroscopy (CDS) technology, which enables label-free cell analysis with single-cell resolution. This innovative approach provides comprehensive insights into bioprocesses, facilitating automated and quantitative assessments crucial for biomedical research. Cytomos' systems are designed to support biopharma and cell therapy applications by offering deep data analysis per cell, thereby enhancing phenotypic drug discovery and stem cell therapy. By leveraging machine learning algorithms, Cytomos provides researchers with the tools necessary to optimize cell-based diagnostics and ensure accurate dosing in therapeutic contexts.

ILC Therapeutics Ltd is a biotechnology company based in Lanarkshire, United Kingdom, established in 2012. The company focuses on modulating the innate immune system through the development of novel peptide therapeutics aimed at treating various conditions, including cancer, atopic dermatitis, psoriasis, and COVID-19. ILC Therapeutics is pioneering a new class of interferon medicines known as hybrid interferons, which combine features from different natural interferon subtypes into a single molecule. This innovative approach seeks to enhance efficacy and improve safety in therapeutic applications, ultimately enabling healthcare professionals to achieve better patient outcomes and advance treatments for serious diseases.

ŌGI Bio is a start-up company emerging from The University of Edinburgh, focused on transforming microbial cultivation and management. The company has developed a modular culturing system that aims to replicate traditional manual flask culturing methods. This innovative system consists of a base unit, which can be customized with retrofittable modules that allow users to add or remove features according to their specific measurement and control needs during the culturing process. By offering this flexible approach, ŌGI Bio seeks to enhance the efficiency and effectiveness of microbial research and applications.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in the research, development, and commercialization of orally available products for fecal microbiota transplantation. By utilizing bacterial communities derived from the human gastrointestinal tract, EnteroBiotix aims to restore health and prevent bacterial infections. The company focuses on creating microbial therapeutics, both allogenic and autologous, designed to address serious unmet medical needs. Its product pipeline includes high-diversity microbiome-modulating drugs tailored to fortify and restore the microbiome, enabling physicians to effectively prevent and treat various debilitating infections and diseases.

Glox Therapeutics specializes in developing precision antibiotic therapies derived from naturally occurring bacteriocins. Their focus is on targeting and eliminating specific, hard-to-treat gram-negative bacterial pathogens that are resistant to traditional antibiotics. By preserving the patient's microbiome, their approach aims to minimize side effects and provide a more balanced treatment strategy, thereby advancing the field of antimicrobial therapy.

Beta Bugs is an insect genetics company specializing in the development and distribution of high-performance Black Soldier Fly breeds aimed at enhancing productivity in the insect protein sector. The company operates a breeding program called HiPer-Fly® and maintains a dedicated egg production site known as The Multiplier®, supplying its breeds to both UK and international markets. By focusing on biotechnology and breeding techniques, Beta Bugs aims to create a sustainable protein source that can effectively replace traditional feed ingredients such as fishmeal and soymeal in livestock, aquaculture, and pet feed. Headquartered at the Easter Bush Campus, a recognized center for animal genetics, Beta Bugs collaborates closely with the Roslin Institute, noted for its pioneering work in animal genetics.

Microplate Dx is a developer of innovative diagnostic technology aimed at addressing the critical global health issue of antimicrobial resistance, which leads to drug-resistant infections. Originating as a spinout from the University of Strathclyde in Glasgow, the company focuses on creating solutions that significantly reduce fatalities associated with these infections. Its core technology utilizes highly sensitive biosensor electrodes paired with miniaturized hydrogel deposits containing antibiotics specifically designed for the infections being tested. This approach offers a low-cost, accurate point-of-care diagnostic device that enables timely and optimal antibiotic prescribing, allowing healthcare providers to deliver effective treatments in under one hour. Microplate Dx's mission is to enhance antibiotic stewardship and proactively combat the rise of antimicrobial resistance worldwide.

Cytomos Limited, established in 2011 and based in Edinburgh, United Kingdom, specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. The company is known for its patented Dielectric Spectroscopy (CDS) technology, which enables label-free cell analysis with single-cell resolution. This innovative approach provides comprehensive insights into bioprocesses, facilitating automated and quantitative assessments crucial for biomedical research. Cytomos' systems are designed to support biopharma and cell therapy applications by offering deep data analysis per cell, thereby enhancing phenotypic drug discovery and stem cell therapy. By leveraging machine learning algorithms, Cytomos provides researchers with the tools necessary to optimize cell-based diagnostics and ensure accurate dosing in therapeutic contexts.

Pneumagen is a biotechnology company based in Saint Andrews, United Kingdom, focused on developing innovative therapies for respiratory tract infections and cancer. Founded in 2016 as a spin-out from the University of St Andrews, the company specializes in glycan-targeted carbohydrate-binding modules (CBMs), which act as a universal therapeutic modality. These CBMs are designed to prevent infection from respiratory viruses, thereby reducing hospitalizations due to disease exacerbation in patients with underlying respiratory conditions. Pneumagen leverages world-class scientific expertise and capabilities in glycobiology to advance its research and development efforts.

Merck, established in 1668, is a global science and technology company operating in three main segments: Life Science, Performance Materials, and Healthcare. The Life Science division (44% of 2023 sales) supplies laboratory consumables and services to researchers, while the Healthcare segment (38%) focuses on developing, manufacturing, and selling branded pharmaceuticals, with key therapeutic areas in oncology, multiple sclerosis, and fertility. The Electronics segment (17%) provides specialty materials for various industries, including semiconductors, electronics, and cosmetics. Merck's extensive global presence spans over 100 countries, with significant operations in Europe, Asia, and emerging markets. The company is committed to partnerships, innovation, and improving lives through its products and solutions.

Cytomos Limited, established in 2011 and based in Edinburgh, United Kingdom, specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. The company is known for its patented Dielectric Spectroscopy (CDS) technology, which enables label-free cell analysis with single-cell resolution. This innovative approach provides comprehensive insights into bioprocesses, facilitating automated and quantitative assessments crucial for biomedical research. Cytomos' systems are designed to support biopharma and cell therapy applications by offering deep data analysis per cell, thereby enhancing phenotypic drug discovery and stem cell therapy. By leveraging machine learning algorithms, Cytomos provides researchers with the tools necessary to optimize cell-based diagnostics and ensure accurate dosing in therapeutic contexts.

BioCaptiva is a company focused on advancing liquid biopsy technology for the early diagnosis and monitoring of challenging-to-detect cancers. The company's innovative platform captures circulating free DNA from patients' blood in greater quantities than existing methods, addressing the limitations of current liquid biopsy tests. By enhancing the ability to detect and monitor cancer, BioCaptiva aims to provide healthcare professionals with improved tools for disease management, ultimately transforming the landscape of cancer diagnostics.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, founded in 2014. The company specializes in discovering and developing novel therapies for inflammatory eye diseases and other autoimmune conditions. Elasmogen's primary innovation lies in its proprietary soloMER technology, which consists of small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are designed to be significantly smaller and more robust than traditional antibodies while avoiding complex patent landscapes. Elasmogen's pipeline includes various candidates targeting autoimmune-mediated inflammatory diseases, such as ELN/21 and ELN/22, as well as soloMER-drug conjugates and NDure, which enhances the plasma half-life of therapeutic molecules. The company has established strategic partnerships with Almac Discovery Ltd and Merck Inc., and it possesses a comprehensive intellectual property portfolio that includes exclusive licenses for over 20 patents across multiple jurisdictions.

ŌGI Bio is a start-up company emerging from The University of Edinburgh, focused on transforming microbial cultivation and management. The company has developed a modular culturing system that aims to replicate traditional manual flask culturing methods. This innovative system consists of a base unit, which can be customized with retrofittable modules that allow users to add or remove features according to their specific measurement and control needs during the culturing process. By offering this flexible approach, ŌGI Bio seeks to enhance the efficiency and effectiveness of microbial research and applications.

Axol Bioscience Ltd., established in 2012 and based in Little Chesterford, United Kingdom, specializes in human cell culture systems for research purposes. The company produces and supplies various types of human cells derived from induced pluripotent stem cells (iPSCs), such as cardiomyocytes, neural stem cells, and astrocytes, along with primary cells like endothelial cells and fibroblasts. Axol also provides essential media, reagents, and growth factors to maintain these cell cultures. Additionally, they offer custom services including iPSC reprogramming, differentiation, genome editing, and cell sourcing tailored to clients' needs. Their products are distributed globally through strategic partners in various countries across Asia, North America, Europe, and internationally.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

UFraction8 is a developer of innovative bioprocessing technology that specializes in scalable solutions for biomass filtration, separation, and dewatering. The company’s technology is applicable to a diverse range of microorganisms, including microalgae, yeast, and bacteria, allowing for the effective sorting of biomass from culture media without the use of harmful flocculants or traditional methods such as centrifugation and membrane filtration. By utilizing advanced microfluidic devices, uFraction8 enhances throughput for industrial-scale applications, including liquid particle processing and selective concentration of pathogens. This technology offers a cost-effective alternative to conventional liquid processing methods, enabling industries to improve efficiency and reduce expenses in their operations.

Pneumagen is a biotechnology company based in Saint Andrews, United Kingdom, focused on developing innovative therapies for respiratory tract infections and cancer. Founded in 2016 as a spin-out from the University of St Andrews, the company specializes in glycan-targeted carbohydrate-binding modules (CBMs), which act as a universal therapeutic modality. These CBMs are designed to prevent infection from respiratory viruses, thereby reducing hospitalizations due to disease exacerbation in patients with underlying respiratory conditions. Pneumagen leverages world-class scientific expertise and capabilities in glycobiology to advance its research and development efforts.

Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in the research, development, and commercialization of orally available products for fecal microbiota transplantation. By utilizing bacterial communities derived from the human gastrointestinal tract, EnteroBiotix aims to restore health and prevent bacterial infections. The company focuses on creating microbial therapeutics, both allogenic and autologous, designed to address serious unmet medical needs. Its product pipeline includes high-diversity microbiome-modulating drugs tailored to fortify and restore the microbiome, enabling physicians to effectively prevent and treat various debilitating infections and diseases.

Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, incorporated in 2018. The company specializes in the development of novel immunotherapies that modulate macrophages, a type of immune cell, to enhance the body’s defense against tumors. By targeting the immunosuppressive tumor microenvironment, Macomics aims to leverage disease-specific macrophage biology, thereby enabling healthcare providers and pharmaceutical companies to offer significant clinical benefits to patients suffering from cancer. Through its innovative approach, Macomics is dedicated to advancing precision medicines in the fight against cancer.

ILC Therapeutics Ltd is a biotechnology company based in Lanarkshire, United Kingdom, established in 2012. The company focuses on modulating the innate immune system through the development of novel peptide therapeutics aimed at treating various conditions, including cancer, atopic dermatitis, psoriasis, and COVID-19. ILC Therapeutics is pioneering a new class of interferon medicines known as hybrid interferons, which combine features from different natural interferon subtypes into a single molecule. This innovative approach seeks to enhance efficacy and improve safety in therapeutic applications, ultimately enabling healthcare professionals to achieve better patient outcomes and advance treatments for serious diseases.

BioCaptiva is a company focused on advancing liquid biopsy technology for the early diagnosis and monitoring of challenging-to-detect cancers. The company's innovative platform captures circulating free DNA from patients' blood in greater quantities than existing methods, addressing the limitations of current liquid biopsy tests. By enhancing the ability to detect and monitor cancer, BioCaptiva aims to provide healthcare professionals with improved tools for disease management, ultimately transforming the landscape of cancer diagnostics.

Pneumagen is a biotechnology company based in Saint Andrews, United Kingdom, focused on developing innovative therapies for respiratory tract infections and cancer. Founded in 2016 as a spin-out from the University of St Andrews, the company specializes in glycan-targeted carbohydrate-binding modules (CBMs), which act as a universal therapeutic modality. These CBMs are designed to prevent infection from respiratory viruses, thereby reducing hospitalizations due to disease exacerbation in patients with underlying respiratory conditions. Pneumagen leverages world-class scientific expertise and capabilities in glycobiology to advance its research and development efforts.

Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, incorporated in 2018. The company specializes in the development of novel immunotherapies that modulate macrophages, a type of immune cell, to enhance the body’s defense against tumors. By targeting the immunosuppressive tumor microenvironment, Macomics aims to leverage disease-specific macrophage biology, thereby enabling healthcare providers and pharmaceutical companies to offer significant clinical benefits to patients suffering from cancer. Through its innovative approach, Macomics is dedicated to advancing precision medicines in the fight against cancer.

Pneumagen is a biotechnology company based in Saint Andrews, United Kingdom, focused on developing innovative therapies for respiratory tract infections and cancer. Founded in 2016 as a spin-out from the University of St Andrews, the company specializes in glycan-targeted carbohydrate-binding modules (CBMs), which act as a universal therapeutic modality. These CBMs are designed to prevent infection from respiratory viruses, thereby reducing hospitalizations due to disease exacerbation in patients with underlying respiratory conditions. Pneumagen leverages world-class scientific expertise and capabilities in glycobiology to advance its research and development efforts.

Censo Biotechnologies Ltd is a stem cell technology company specializing in the provision of human cells and contract research services aimed at drug discovery, toxicity testing, and cell banking. Utilizing its induced pluripotent stem cells (iPSCs) technology, Censo generates stem cells from skin or blood samples provided by donors. The company's offerings include human tissue sample procurement, iPSC generation, genome editing, differentiated cell protocol development, and the production of specific differentiated cell lineages. Censo focuses on supporting research related to neurodegenerative and neuro-inflammatory diseases by providing gene editing capabilities using CRISPR technology and a diverse range of existing human iPSC lines. Founded in 2008 and headquartered in Edinburgh, with an additional office in Cambridge, Censo aims to facilitate advancements in biotechnology through its innovative services.

Censo Biotechnologies Ltd is a stem cell technology company specializing in the provision of human cells and contract research services aimed at drug discovery, toxicity testing, and cell banking. Utilizing its induced pluripotent stem cells (iPSCs) technology, Censo generates stem cells from skin or blood samples provided by donors. The company's offerings include human tissue sample procurement, iPSC generation, genome editing, differentiated cell protocol development, and the production of specific differentiated cell lineages. Censo focuses on supporting research related to neurodegenerative and neuro-inflammatory diseases by providing gene editing capabilities using CRISPR technology and a diverse range of existing human iPSC lines. Founded in 2008 and headquartered in Edinburgh, with an additional office in Cambridge, Censo aims to facilitate advancements in biotechnology through its innovative services.

Wobble Genomics is a biotechnology firm focused on the discovery and detection of nucleic acid biomarkers, utilizing advanced RNA and DNA sequencing techniques. The company aims to achieve unprecedented sensitivity and accuracy in biomarker identification by integrating biochemistry with bioinformatics. This innovative approach enhances sequencing efficiency, allowing medical researchers to optimize sampling processes while reducing costs. By streamlining the discovery of nucleic acid biomarkers, Wobble Genomics contributes to advancements in medical research and diagnostics.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, that specializes in the development and commercialization of recombinant blood factors for the treatment of hemophilia. Founded in 2009, the company focuses on producing Factor VIII, a complex and unstable protein essential for blood clotting. ProFactor Pharma is committed to creating commercial and Good Manufacturing Practice (GMP) compliant cell lines that produce recombinant Factor VIII. By leveraging proprietary high-expressing cell lines and innovative manufacturing technologies, the company aims to provide healthcare institutions with affordable and effective treatment options for hemophilia, a serious genetic disorder that impairs the body’s ability to form blood clots and can lead to severe health complications.

MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, that focuses on developing innovative treatments for patients with autoimmune diseases and cancers. Founded in 2009, the company is dedicated to creating first-in-class antibody therapies, particularly its lead product, annexuzlimab, a monoclonal antibody designed to target and inhibit annexin-A1. This approach aims to modulate both the innate and adaptive immune systems, thereby enhancing treatment options for healthcare providers and improving patient outcomes. Through its specialized research and development efforts, MedAnnex seeks to address significant unmet medical needs in the field of immunotherapy.

Censo Biotechnologies Ltd is a stem cell technology company specializing in the provision of human cells and contract research services aimed at drug discovery, toxicity testing, and cell banking. Utilizing its induced pluripotent stem cells (iPSCs) technology, Censo generates stem cells from skin or blood samples provided by donors. The company's offerings include human tissue sample procurement, iPSC generation, genome editing, differentiated cell protocol development, and the production of specific differentiated cell lineages. Censo focuses on supporting research related to neurodegenerative and neuro-inflammatory diseases by providing gene editing capabilities using CRISPR technology and a diverse range of existing human iPSC lines. Founded in 2008 and headquartered in Edinburgh, with an additional office in Cambridge, Censo aims to facilitate advancements in biotechnology through its innovative services.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in the research, development, and commercialization of orally available products for fecal microbiota transplantation. By utilizing bacterial communities derived from the human gastrointestinal tract, EnteroBiotix aims to restore health and prevent bacterial infections. The company focuses on creating microbial therapeutics, both allogenic and autologous, designed to address serious unmet medical needs. Its product pipeline includes high-diversity microbiome-modulating drugs tailored to fortify and restore the microbiome, enabling physicians to effectively prevent and treat various debilitating infections and diseases.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Synpromics Ltd. is a biotechnology company based in Edinburgh, United Kingdom, founded in 2010. The company specializes in the development and commercialization of synthetic promoters, which are crucial for controlling gene expression and regulation. Synpromics aims to enhance human health by facilitating the creation of safer and more effective cell and gene therapies. Utilizing proprietary genomics and bioinformatics, along with an intelligent data-driven design approach, Synpromics provides a multi-dimensional bioinformatics database that supports product-specific promoter design and selection. This technology empowers biological researchers and developers in the AgBio sector to innovate and improve efficacy and safety in the development of new medicines and bioprocessing applications. As of August 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

TC Biopharm Limited is a clinical development company based in Edinburgh, United Kingdom, that specializes in the development, manufacturing, and commercialization of innovative cell-based products aimed at treating cancer and severe viral infections. The company’s flagship product, ImmuniCell, is an autologous therapy that expands patient-derived cells in a cleanroom environment to create treatments for various tumor types and viral infections. TC Biopharm is advancing its pipeline through Phase II/III clinical studies, focusing on conditions such as renal cell carcinoma, non-small cell lung cancer, and melanoma. The company is committed to developing safer, more effective, and durable therapies, utilizing its proprietary allogeneic gamma delta T cell platform to harness the innate immune response against malignancies and infections. Through strategic partnerships and collaborations with organizations like Medinet and bluebird bio, TC Biopharm aims to enhance its capabilities and accelerate the delivery of its therapies to patients.

Mironid Limited is a biotechnology company based in Newhouse, United Kingdom, that specializes in drug discovery and development. Founded in 2014, Mironid focuses on creating innovative drug candidate molecules that modulate key cell signaling proteins to address degenerative kidney diseases, chronic inflammatory diseases, and cancer. The company's pipeline includes unique compounds designed to treat these conditions, utilizing a Physiology Mirroring Approach that aligns drug target environments with those found in living cells. Mironid aims to identify and validate novel drug targets, particularly in areas with significant unmet medical needs, by leveraging advanced technologies to streamline and enhance the drug discovery process. Through its dedicated efforts, Mironid seeks to develop differentiated therapies that improve patient health and quality of life.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in the research, development, and commercialization of orally available products for fecal microbiota transplantation. By utilizing bacterial communities derived from the human gastrointestinal tract, EnteroBiotix aims to restore health and prevent bacterial infections. The company focuses on creating microbial therapeutics, both allogenic and autologous, designed to address serious unmet medical needs. Its product pipeline includes high-diversity microbiome-modulating drugs tailored to fortify and restore the microbiome, enabling physicians to effectively prevent and treat various debilitating infections and diseases.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, established in 2006. The company specializes in the development and commercialization of medical devices and pharmaceuticals centered around Lamellasomes, a synthetic substance that imitates the function of extra-alveolar lamellar bodies. Lamellar Biomedical's innovative products target various respiratory diseases, including cystic fibrosis, and conditions such as radiotherapy-induced xerostomia and dry eye disease. The company’s therapeutic platform leverages anti-infective properties to enhance antibiotic efficacy and protect lung tissues, particularly in complex cases like idiopathic pulmonary fibrosis. Additionally, it facilitates the intracellular delivery of genetic material for pulmonary disease treatment, aiming to provide transformative therapies for severe respiratory conditions. Lamellar Biomedical was previously known as Macrocom (964) Limited before adopting its current name in February 2007.

Synpromics Ltd. is a biotechnology company based in Edinburgh, United Kingdom, founded in 2010. The company specializes in the development and commercialization of synthetic promoters, which are crucial for controlling gene expression and regulation. Synpromics aims to enhance human health by facilitating the creation of safer and more effective cell and gene therapies. Utilizing proprietary genomics and bioinformatics, along with an intelligent data-driven design approach, Synpromics provides a multi-dimensional bioinformatics database that supports product-specific promoter design and selection. This technology empowers biological researchers and developers in the AgBio sector to innovate and improve efficacy and safety in the development of new medicines and bioprocessing applications. As of August 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, founded in 2014. The company specializes in discovering and developing novel therapies for inflammatory eye diseases and other autoimmune conditions. Elasmogen's primary innovation lies in its proprietary soloMER technology, which consists of small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are designed to be significantly smaller and more robust than traditional antibodies while avoiding complex patent landscapes. Elasmogen's pipeline includes various candidates targeting autoimmune-mediated inflammatory diseases, such as ELN/21 and ELN/22, as well as soloMER-drug conjugates and NDure, which enhances the plasma half-life of therapeutic molecules. The company has established strategic partnerships with Almac Discovery Ltd and Merck Inc., and it possesses a comprehensive intellectual property portfolio that includes exclusive licenses for over 20 patents across multiple jurisdictions.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, founded in 2014. The company specializes in discovering and developing novel therapies for inflammatory eye diseases and other autoimmune conditions. Elasmogen's primary innovation lies in its proprietary soloMER technology, which consists of small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are designed to be significantly smaller and more robust than traditional antibodies while avoiding complex patent landscapes. Elasmogen's pipeline includes various candidates targeting autoimmune-mediated inflammatory diseases, such as ELN/21 and ELN/22, as well as soloMER-drug conjugates and NDure, which enhances the plasma half-life of therapeutic molecules. The company has established strategic partnerships with Almac Discovery Ltd and Merck Inc., and it possesses a comprehensive intellectual property portfolio that includes exclusive licenses for over 20 patents across multiple jurisdictions.

TC Biopharm Limited is a clinical development company based in Edinburgh, United Kingdom, that specializes in the development, manufacturing, and commercialization of innovative cell-based products aimed at treating cancer and severe viral infections. The company’s flagship product, ImmuniCell, is an autologous therapy that expands patient-derived cells in a cleanroom environment to create treatments for various tumor types and viral infections. TC Biopharm is advancing its pipeline through Phase II/III clinical studies, focusing on conditions such as renal cell carcinoma, non-small cell lung cancer, and melanoma. The company is committed to developing safer, more effective, and durable therapies, utilizing its proprietary allogeneic gamma delta T cell platform to harness the innate immune response against malignancies and infections. Through strategic partnerships and collaborations with organizations like Medinet and bluebird bio, TC Biopharm aims to enhance its capabilities and accelerate the delivery of its therapies to patients.

Mironid Limited is a biotechnology company based in Newhouse, United Kingdom, that specializes in drug discovery and development. Founded in 2014, Mironid focuses on creating innovative drug candidate molecules that modulate key cell signaling proteins to address degenerative kidney diseases, chronic inflammatory diseases, and cancer. The company's pipeline includes unique compounds designed to treat these conditions, utilizing a Physiology Mirroring Approach that aligns drug target environments with those found in living cells. Mironid aims to identify and validate novel drug targets, particularly in areas with significant unmet medical needs, by leveraging advanced technologies to streamline and enhance the drug discovery process. Through its dedicated efforts, Mironid seeks to develop differentiated therapies that improve patient health and quality of life.

Caldan Therapeutics Ltd is a biotechnology company formed as a spinout from the University of Glasgow and the University of Southern Denmark. The company is focused on developing innovative therapeutics that target free fatty acid receptors, which play a significant role in the pathophysiology of metabolic diseases such as Type 2 Diabetes (T2D). The collaboration between Professors Graeme Milligan and Trond Ulven has led to the identification of these receptors as promising targets for addressing various aspects of T2D, including insulin secretion, sensitivity, and cellular protection. In addition to T2D, Caldan Therapeutics is exploring the potential of its technology to treat other conditions, including non-alcoholic steatohepatitis (NASH) and inflammatory diseases.

Biogelx Ltd. is a biomaterials company based in Newhouse, United Kingdom, that specializes in the development and supply of tuneable peptide hydrogels. Founded in 2012, the company focuses on creating hydrogels specifically designed for cell culture applications, including cell-based toxicity screening, cancer research, and the reduction of animal testing. These hydrogels mimic the chemical and physical properties of natural tissues, allowing researchers to study and manipulate cells within a realistic three-dimensional environment. Biogelx's patented products offer significant advantages for academic institutions, medical researchers, and pharmaceutical companies, providing a viable alternative to existing 3D cell culture solutions. The company's innovative approach aims to facilitate advancements in fundamental cell research and has potential applications in cell therapy and regenerative medicine. Biogelx's hydrogels are currently marketed in the United States, Europe, and Asia.

Clyde Biosciences, established in 2012 and headquartered in Glasgow, UK, specializes in providing cardiac cell analysis solutions for the pharmaceutical and biotechnology industries, both domestically and internationally. The company's core offerings include cellOPTIQ, an optical action potential assay, and XTENDSR, a solution for measuring drug-induced changes on cardiac sarcoplasmic reticulum function. These tools enable clients to gain insights into the mechanisms and effects of drug compounds on human cells, aiding in the evaluation of drug toxicity and cardiotoxicity risk during the research and development phase.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, that specializes in the development and commercialization of recombinant blood factors for the treatment of hemophilia. Founded in 2009, the company focuses on producing Factor VIII, a complex and unstable protein essential for blood clotting. ProFactor Pharma is committed to creating commercial and Good Manufacturing Practice (GMP) compliant cell lines that produce recombinant Factor VIII. By leveraging proprietary high-expressing cell lines and innovative manufacturing technologies, the company aims to provide healthcare institutions with affordable and effective treatment options for hemophilia, a serious genetic disorder that impairs the body’s ability to form blood clots and can lead to severe health complications.

Relitect Limited is a technology company based in Motherwell, United Kingdom, focused on developing innovative diagnostic solutions for the life sciences industry. Founded in 2014, Relitect specializes in a novel assay platform that enables label-free electrochemical detection of binding events. This proprietary technology allows for the highly sensitive analysis of proteins, small molecules, and nucleic acids, making it suitable for clinical diagnostics and research applications. By utilizing small sample volumes and a multiplexed format, Relitect's technology minimizes sample interference and eliminates the potential for cross-talk between labeled reagents, enhancing the accuracy of biomarker detection.

DestiNA Genomics Ltd. is a molecular diagnostic company based in Edinburgh, United Kingdom, and was incorporated in 2010 as a spin-out from the University of Edinburgh. The company specializes in a novel chemical-based system for the detection of nucleic acids and single nucleotide polymorphisms, distinguishing itself from existing enzymatic methods. DestiNA Genomics offers a range of reagents and probes for detecting nucleic acids and mutations, as well as probe sets and assays aimed at drug development and profiling. Its technology is particularly effective for direct detection of micro-RNAs and is being integrated into various detection platforms, including colorimetric, fluorescent, and electrochemical systems. Additionally, DestiNA has established a subsidiary in Spain, DestiNA Genomica SL, to exploit its technology in collaboration with local partners. The company is committed to advancing diagnostic capabilities in areas such as cancer biomarkers, inherited diseases, and infectious diseases.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, that specializes in the development and commercialization of recombinant blood factors for the treatment of hemophilia. Founded in 2009, the company focuses on producing Factor VIII, a complex and unstable protein essential for blood clotting. ProFactor Pharma is committed to creating commercial and Good Manufacturing Practice (GMP) compliant cell lines that produce recombinant Factor VIII. By leveraging proprietary high-expressing cell lines and innovative manufacturing technologies, the company aims to provide healthcare institutions with affordable and effective treatment options for hemophilia, a serious genetic disorder that impairs the body’s ability to form blood clots and can lead to severe health complications.

NuCana plc is a UK-based, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. It specializes in transforming widely-used chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology. NuCana's pipeline includes Acelarin, in Phase III trials for biliary tract and metastatic pancreatic cancers, and NUC-3373 & NUC-7738, in Phase I trials for advanced solid tumors. The company collaborates with academic institutions for research and licensing agreements. NuCana was established in 1997 and is headquartered in Edinburgh, with a focus on the U.S. market.

NuCana plc is a UK-based, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. It specializes in transforming widely-used chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology. NuCana's pipeline includes Acelarin, in Phase III trials for biliary tract and metastatic pancreatic cancers, and NUC-3373 & NUC-7738, in Phase I trials for advanced solid tumors. The company collaborates with academic institutions for research and licensing agreements. NuCana was established in 1997 and is headquartered in Edinburgh, with a focus on the U.S. market.

Synpromics Ltd. is a biotechnology company based in Edinburgh, United Kingdom, founded in 2010. The company specializes in the development and commercialization of synthetic promoters, which are crucial for controlling gene expression and regulation. Synpromics aims to enhance human health by facilitating the creation of safer and more effective cell and gene therapies. Utilizing proprietary genomics and bioinformatics, along with an intelligent data-driven design approach, Synpromics provides a multi-dimensional bioinformatics database that supports product-specific promoter design and selection. This technology empowers biological researchers and developers in the AgBio sector to innovate and improve efficacy and safety in the development of new medicines and bioprocessing applications. As of August 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, founded in 2014. The company specializes in discovering and developing novel therapies for inflammatory eye diseases and other autoimmune conditions. Elasmogen's primary innovation lies in its proprietary soloMER technology, which consists of small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are designed to be significantly smaller and more robust than traditional antibodies while avoiding complex patent landscapes. Elasmogen's pipeline includes various candidates targeting autoimmune-mediated inflammatory diseases, such as ELN/21 and ELN/22, as well as soloMER-drug conjugates and NDure, which enhances the plasma half-life of therapeutic molecules. The company has established strategic partnerships with Almac Discovery Ltd and Merck Inc., and it possesses a comprehensive intellectual property portfolio that includes exclusive licenses for over 20 patents across multiple jurisdictions.

Ubiquigent Limited is a biotechnology company based in Dundee, United Kingdom, founded in 2009. It specializes in the development and supply of high-quality reagents, kits, and drug discovery assay development services, focusing on the ubiquitin and ubiquitin-like signaling systems. The company provides protein degradation-focused drug discovery services and designs novel deubiquitylase (DUB) enzyme inhibitors as potential therapeutics for addressing unmet medical needs. Ubiquigent collaborates with both academic and pharmaceutical researchers, supporting fundamental scientific discovery and the exploration of innovative drug candidates targeting DUBs. Its hybrid business model emphasizes the generation of intellectual property while maintaining an internal pipeline of drug discovery programs aimed at optimizing compounds for critical therapeutic areas.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, that specializes in the development and commercialization of recombinant blood factors for the treatment of hemophilia. Founded in 2009, the company focuses on producing Factor VIII, a complex and unstable protein essential for blood clotting. ProFactor Pharma is committed to creating commercial and Good Manufacturing Practice (GMP) compliant cell lines that produce recombinant Factor VIII. By leveraging proprietary high-expressing cell lines and innovative manufacturing technologies, the company aims to provide healthcare institutions with affordable and effective treatment options for hemophilia, a serious genetic disorder that impairs the body’s ability to form blood clots and can lead to severe health complications.

Fixed Phage was founded with the aim of developing new products for various industries from our platform technology. Each of our core technologies is comprehensively described and protected by our IP portfolio. We work at our custom designed laboratory and support infrastructure facilities located at the prestigious West of Scotland Science Park. Our in-house abilities include all work required to identify, manufacture and work with bacteriophage. Fixed Phage continually invests in innovation and our team presents at conferences and exhibitions around the world. To learn about whether we will be presenting near you, please follow us on social media.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, established in 2006. The company specializes in the development and commercialization of medical devices and pharmaceuticals centered around Lamellasomes, a synthetic substance that imitates the function of extra-alveolar lamellar bodies. Lamellar Biomedical's innovative products target various respiratory diseases, including cystic fibrosis, and conditions such as radiotherapy-induced xerostomia and dry eye disease. The company’s therapeutic platform leverages anti-infective properties to enhance antibiotic efficacy and protect lung tissues, particularly in complex cases like idiopathic pulmonary fibrosis. Additionally, it facilitates the intracellular delivery of genetic material for pulmonary disease treatment, aiming to provide transformative therapies for severe respiratory conditions. Lamellar Biomedical was previously known as Macrocom (964) Limited before adopting its current name in February 2007.

Biogelx Ltd. is a biomaterials company based in Newhouse, United Kingdom, that specializes in the development and supply of tuneable peptide hydrogels. Founded in 2012, the company focuses on creating hydrogels specifically designed for cell culture applications, including cell-based toxicity screening, cancer research, and the reduction of animal testing. These hydrogels mimic the chemical and physical properties of natural tissues, allowing researchers to study and manipulate cells within a realistic three-dimensional environment. Biogelx's patented products offer significant advantages for academic institutions, medical researchers, and pharmaceutical companies, providing a viable alternative to existing 3D cell culture solutions. The company's innovative approach aims to facilitate advancements in fundamental cell research and has potential applications in cell therapy and regenerative medicine. Biogelx's hydrogels are currently marketed in the United States, Europe, and Asia.

NuCana plc is a UK-based, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. It specializes in transforming widely-used chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology. NuCana's pipeline includes Acelarin, in Phase III trials for biliary tract and metastatic pancreatic cancers, and NUC-3373 & NUC-7738, in Phase I trials for advanced solid tumors. The company collaborates with academic institutions for research and licensing agreements. NuCana was established in 1997 and is headquartered in Edinburgh, with a focus on the U.S. market.

NuCana plc is a UK-based, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments. It specializes in transforming widely-used chemotherapy agents into more effective and safer medicines using its proprietary ProTide technology. NuCana's pipeline includes Acelarin, in Phase III trials for biliary tract and metastatic pancreatic cancers, and NUC-3373 & NUC-7738, in Phase I trials for advanced solid tumors. The company collaborates with academic institutions for research and licensing agreements. NuCana was established in 1997 and is headquartered in Edinburgh, with a focus on the U.S. market.

TPP is a UK-based preclinical-stage drug development company focused on nervous system disorders, immunology, and oncology. They in-license and develop intellectual properties obtained from research institutions, and the resultant products are either distributed via spin-outs or through licensing to the biotech/pharmaceutical sector.

Actual Analytics Limited specializes in behavior analysis solutions for scientific research, leveraging advanced video analysis technology to monitor animal behavior automatically. The company’s flagship products include ActualTrack, which tracks the movements of lab animals such as rodents, drosophila, and zebrafish, and Actual Home Cage Analysis (ActualHCA), which facilitates non-invasive data collection and automated analysis of behaviors in group-housed rodents. This technology is particularly valuable in drug development for diseases affecting the Central Nervous System, allowing researchers to streamline the monitoring process, reduce errors, and cut costs associated with manual observation. Established in 2009 and headquartered in Edinburgh, United Kingdom, Actual Analytics distributes its products in various markets, including the United States, Spain, Taiwan, China, and Germany.

Syntropharma Limited is an emerging pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the development and distribution of pharmaceutical products, particularly focusing on skin patches that deliver proven medicines for various diseases, including neurological disorders such as Alzheimer's disease and depression. By reformulating commercially successful generic compounds into transdermal applications, Syntropharma aims to enhance their clinical profiles. The company is committed to creating a pipeline of innovative transdermal products protected by strong intellectual property, which it plans to out-license to pharmaceutical partners for broader market reach.

Lab901 Limited engages in the development and production of automated gel electrophories in the United Kingdom. It offers ScreenTape P200 variant, which allows scientists in expressing and purifying recombinant proteins and monoclonal antibodies to carry out SDS-PAGE and analysis; ScreenTape R6K that is developed for reproducible RNA characterisation and quality control; and ScreenTape D800, which separates DNA fragments.

Big DNA Ltd was set up in 2007 by Dr John March, as a spin out company from the Moredun Research Institute at Edinburgh University, to further develop and commercialise new vaccination technologies. Based at Roslin BioCentre, the company currently employs 7 people.

Lab901 Limited engages in the development and production of automated gel electrophories in the United Kingdom. It offers ScreenTape P200 variant, which allows scientists in expressing and purifying recombinant proteins and monoclonal antibodies to carry out SDS-PAGE and analysis; ScreenTape R6K that is developed for reproducible RNA characterisation and quality control; and ScreenTape D800, which separates DNA fragments.

CXR Biosciences Limited specializes in preclinical services focused on investigative and mechanistic toxicology, exploratory toxicology, and pharmacokinetics/toxicokinetics. The company evaluates hazards and risks associated with compounds, provides solutions for chemical design and candidate selection, and generates essential metabolic profiling data. CXR Biosciences employs advanced technologies, including in vivo and in vitro methods, genomics, microarrays, and mechanistic assays, to support its clients in ensuring compound safety and optimizing drug development processes. The company serves a diverse clientele, including pharmaceutical, agrochemical, industrial, and biotechnology sectors, along with academic institutions. Established in 2000 and based in Dundee, United Kingdom, CXR Biosciences has developed strong collaborations with over sixty customers and partners to enhance drug development and chemical safety assessment practices.

Big DNA Ltd was set up in 2007 by Dr John March, as a spin out company from the Moredun Research Institute at Edinburgh University, to further develop and commercialise new vaccination technologies. Based at Roslin BioCentre, the company currently employs 7 people.

Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.

DC Biosciences Ltd is a biotechnology company based in Dundee, United Kingdom, focused on providing innovative proteomics services and molecular biology solutions to pharmaceutical and biotech firms. Established in 2006 and rebranded from Dundee Cell Products Ltd in 2016, the company specializes in quantitative proteomics technologies that facilitate various preclinical activities in drug discovery. Its offerings include stable isotope labeling with amino acids in cell culture reagents, such as SILAC cell culture media and dialyzed sera, alongside click chemistry reagents. These products support crucial processes such as biomarker discovery and validation, as well as drug re-profiling and repositioning, enabling faster and safer drug development.

Syntropharma Limited is an emerging pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the development and distribution of pharmaceutical products, particularly focusing on skin patches that deliver proven medicines for various diseases, including neurological disorders such as Alzheimer's disease and depression. By reformulating commercially successful generic compounds into transdermal applications, Syntropharma aims to enhance their clinical profiles. The company is committed to creating a pipeline of innovative transdermal products protected by strong intellectual property, which it plans to out-license to pharmaceutical partners for broader market reach.

Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.

Lab901 Limited engages in the development and production of automated gel electrophories in the United Kingdom. It offers ScreenTape P200 variant, which allows scientists in expressing and purifying recombinant proteins and monoclonal antibodies to carry out SDS-PAGE and analysis; ScreenTape R6K that is developed for reproducible RNA characterisation and quality control; and ScreenTape D800, which separates DNA fragments.